Physician profile
Misbat Chaudry
NPI 1447561337
$1,640.84
in general payments reported to CMS, 2019-2025
28 companies · $86.00 in 2025
The $86.00 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $291 · 2021: $214 · 2022: $189 · 2023: $416 · 2024: $42.29 · 2025: $86.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $141.81 | 2019-2023 | Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $132.98 | 2019-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $130.14 | 2019-2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $127.74 | 2019-2025 | |
| Incyte Corporation | $118.43 | 2020-2023 | Jakafi |
| Daiichi Sankyo INC. | $90.17 | 2021-2023 | Enhertu |
| Celgene Corporation | $83.77 | 2021-2023 | Pomalyst |
| Pfizer INC. | $75.15 | 2019-2023 | |
| Amgen INC. | $74.99 | 2019 | |
| Clovis Oncology, INC. | $74.99 | 2019 | |
| Genentech USA, INC. | $74.50 | 2019-2020 | |
| Foundation Medicine, INC. | $62.99 | 2022-2023 | |
| Stemline Therapeutics INC. | $48.55 | 2020 | |
| Rigel Pharmaceuticals, INC. | $48.38 | 2022-2023 | Tavalisse, Rezlidhia |
| E.R. Squibb & Sons, L.L.C. | $42.97 | 2019-2025 | Opdivo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $40.85 | 2022-2024 | Onivyde |
| Astellas Pharma US INC | $35.20 | 2020-2024 | Padcev |
| Jazz Pharmaceuticals INC. | $30.25 | 2020 | |
| Eisai INC. | $29.77 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $24.64 | 2023 | Calquence |
| Abbvie INC. | $21.77 | 2025 | |
| Karyopharm Therapeutics INC. | $21.46 | 2023 | Xpovio |
| Tactile Systems Technology INC | $20.83 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $20.25 | 2021 | |
| Beigene USA, INC. | $19.74 | 2023 | Brukinsa |
| Morphosys, US INC. | $18.90 | 2023 | Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $18.51 | 2020 | |
| Janssen Biotech, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misbat Chaudry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.